


Drugs@FDA: FDA Approved Drug Products

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=basicsearch.process)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug Products&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=basicsearch.process)



 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=basicsearch.process)

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 022260

Company: ACTELION PHARMS LTD

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=022260\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process%26varapplno=022260)

Products on NDA 022260

CSVExcelPrint

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code
VELETRI	EPOPROSTENOL SODIUM	EQ 1.5MG BASE/VIAL	INJECTABLE;INJECTION	Prescription	Yes	None
VELETRI	EPOPROSTENOL SODIUM	EQ 0.5MG BASE/VIAL	INJECTABLE;INJECTION	Prescription	Yes	None

Showing 1 to 2 of 2 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 022260

Original Approvals or Tentative Approvals

CSVExcelPrint

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews
06/27/2008	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/017111Orig1s01.pdf) Review (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/017111Orig1s01.pdf) Summary Review (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/017111Orig1s01.pdf)

Showing 1 to 1 of 1 entries

Supplements**CSVExcelPrint**

Action Date	Submission	Submission Classification	Letters, Reviews, Labels, Patient Package Insert
07/18/2016	SUPPL-8	Manufacturing (CMC)	
03/03/2015	SUPPL-7	Manufacturing (CMC)	
06/28/2012	SUPPL-5	Manufacturing (CMC)	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022260s01.pdf)
03/30/2011	SUPPL-4	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022260s01.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2011/022260s01.pdf)
08/23/2010	SUPPL-2	Labeling- Proprietary Name Change	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022260s01.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2010/022260s01.pdf)

Showing 1 to 5 of 5 entries

Labels for NDA 022260

